Irinotecan pharmacogenetics: is it time to intervene?
Howard L
HL
McLeod
James W
JW
Watters
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005838:Genotype; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D000077146:Irinotecan; D009503:Neutropenia / Q000139:chemically induced*; D012306:Risk; D059004:Topoisomerase I Inhibitors; D000099148:UGT1A1 Enzyme
D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin; D004791:Enzyme Inhibitors; D014453:Glucuronosyltransferase; D000077146:Irinotecan; D059004:Topoisomerase I Inhibitors; D000099148:UGT1A1 Enzyme